How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Fibromyalgia Market
- By Treatment Type: Pharmacological Treatments, Non-Pharmacological Therapies, Complementary and Alternative Medicine
- By Pharmacological Treatments: Analgesics, Antidepressants, Anticonvulsants, Muscle Relaxants
- By Non-Pharmacological Therapies: Physical Therapy, Cognitive Behavioral Therapy, Exercise Therapy, Occupational Therapy
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Patient Demographics: Adult Females, Adult Males, Geriatric Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Treatments leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Fibromyalgia Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 3
Pharmacological Treatments 4
Non-Pharmacological Therapies 4
Distribution Channel 3
Patient Demographics 3
Companies profiled
Pfizer Inc.
Eli Lilly and Company
AbbVie Inc.
Mylan N.V. (now part of Viatris)
Teva Pharmaceutical Industries Ltd.
Jazz Pharmaceuticals plc
H. Lundbeck A/S
AstraZeneca plc
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Mitsubishi Tanabe Pharma Corporation
Zydus Cadila
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Jazz Pharmaceuticals plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bausch Health Companies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Zydus Cadila
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Meda AB (subsidiary of Mylan/Viatris)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Grünenthal GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ipsen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,383M by 2033 · 4.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Treatments56.8
- Non-Pharmacological Therapies29.7
- Complementary and Alternative Medicine13.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,449M → $2,267M · 5.8%
Europe$1,010M → $1,457M · 4.7%
Asia Pacific$921.8M → $1,201M · 3.4%
Latin America$570.6M → $797.6M · 4.3%
Middle East and Africa$438.9M → $602.1M · 4.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.752026
4.752027
4.772028
4.772029
4.782030
4.802031
4.822032
4.822033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.15.0
- Eli Lilly and Company21.9
- AbbVie Inc.9.5
- Mylan N.V. (now part of Viatris)5.0
- Teva Pharmaceutical Industries Ltd.8.3
- Jazz Pharmaceuticals plc12.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type25.6%
Pharmacological Treatments13.7%
Non-Pharmacological Therapies21.5%
Distribution Channel10.6%
Patient Demographics28.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.9
- Europe23.0
- Asia Pacific19.0
- Latin America12.6
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 76 | 90 | 80 | 87 | 93 | 86 | 85 |
| Eli Lilly and Company | 88 | 78 | 83 | 76 | 81 | 84 | 82 |
| AbbVie Inc. | 77 | 78 | 68 | 88 | 66 | 81 | 76 |
| Mylan N.V. (now part of Viatris) | 73 | 75 | 68 | 63 | 77 | 67 | 71 |
| Teva Pharmaceutical Industries Ltd. | 74 | 63 | 52 | 62 | 53 | 59 | 61 |
| Jazz Pharmaceuticals plc | 47 | 63 | 58 | 57 | 58 | 49 | 55 |
| H. Lundbeck A/S | 44 | 60 | 44 | 47 | 63 | 48 | 51 |
| AstraZeneca plc | 57 | 59 | 53 | 44 | 49 | 55 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Eli Lilly and Company
- AbbVie Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Eli Lilly and Company | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| AbbVie Inc. | ✓ | ✓ | − | ◐ | ✓ | ◐ |
| Mylan N.V. (now part of Viatris) | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | − | − | − | ◐ |
| Jazz Pharmaceuticals plc | − | ◐ | ◐ | − | ◐ | − |
| H. Lundbeck A/S | − | ◐ | − | ◐ | ◐ | − |
| AstraZeneca plc | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.85
2Eli Lilly and Company82
3AbbVie Inc.76
4Mylan N.V. (now part of Viatris)71
5Teva Pharmaceutical Industries Ltd.61
6Jazz Pharmaceuticals plc55
7AstraZeneca plc53
8H. Lundbeck A/S51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Eli Lilly and Company
Challenger2
Strong scale, closing on the leaders.
AbbVie Inc.Mylan N.V. (now part of Viatris)
Contender1
Focused players with pockets of strength.
Teva Pharmaceutical Industries Ltd.
Niche3
Specialists in a single segment or region.
Jazz Pharmaceuticals plcH. Lundbeck A/SAstraZeneca plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Fibromyalgia Market — a $381M beachhead inside a $5.52B market.
Beachhead (SOM)$381Mobtainable near-term
Serviceable (SAM)$2.26Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Pharmacological Treatments
Best fit — highest urgency & budget in Treatment Type.
Economic buyer78 fit
Non-Pharmacological Therapies
Strong fit — clear ROI and a fast path to value.
End user64 fit
Complementary and Alternative Medicine
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pharmacological Treatments & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Non-Pharmacological Therapies
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Fibromyalgia Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation12%
Closed-won7%
$20.3KCAC
$88KLTV
4.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Fibromyalgia Market is a high-growth opportunity — $1.08B by 2033, compounding at 10.8%.
TAM · 2025$476Mtoday
TAM · 2033$1.08Bforecast
CAGR10.8%2027–2033
Cumulative$6.68Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.08BTotal addressable market
SAM$421MServiceable available market
SOM$88MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.8% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.08BLarge & growingTAM by 2033 at 10.8% CAGR
$421MServiceable nowreachable with today’s model
$88MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$842MBear7.0% CAGR
$1.08BBase10.8% CAGR
$1.38BBull14.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pharmacological Treatments optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Fibromyalgia Market — a $7.60B market by 2033. Plan: grow share from 7.6% to 12.5%.
Market size · 2033$7.60Btotal addressable
Market CAGR7.0%2027–2033
Target share12.5%from 7.6% today
Revenue ambition$950Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 12.5% | Ahead |
| Revenue | $553M | $950M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.8% | 44.4% | At risk |
| Customer retention | 91.6% | 93.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Pharmacological Treatments capability
A defensible second engine — invest in Pharmacological Treatments to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pharmacological Treatments
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $130M capacity & capability investment
- Greenlight bolt-on M&A in Pharmacological Treatments
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Fibromyalgia Market conversation — a $4.84B market you can size, segment and defend in minutes.
Market size · 2033$4.84Btotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,544+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Pfizer Inc.Eli Lilly and CompanyAbbVie Inc.Mylan N.V. (now part of Viatris)Teva Pharmaceutical Industries Ltd.Jazz Pharmaceuticals plcH. Lundbeck A/SAstraZeneca plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Fibromyalgia Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Fibromyalgia Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Fibrosarcoma Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportFibroscan Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFibrosis Drug Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportFibrous Filters Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportFibrous Glass Reinforced Plastics Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFibrous Insulation Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportFicin Proteinase Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportFidelity Sound Receiver Market
Market size, share, segmentation and regional forecast.
$751M market · 2025 base year
View reportFIDO Device Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportFiducial Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportField Artillery Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportField Assembly Optical Connector Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.